Nonfibrillar diffuse amyloid deposition due to a gamma42-secretase site mutation points to an essential role for N-truncated Abeta42 in Alzheimer's disease

Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659 · see citing works

The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor

Kang, J., Lemaire, H.-G., Unterbeck, A., Salbaum, J. M., Masters, C. L., Grzeschik, K.-H., Multhaup, G., Beyreuther, K., & Müller-Hill, B. (1987) · Nature · doi:10.1038/325733a0 · Cited by 4,619 · see citing works

β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACE

Vassar, R., Bennett, B. D., Babu-Khan, S., Kahn, S., Mendiaz, E. A., Denis, P., Teplow, D. B., Ross, S., Amarante, P., Loeloff, R., et al. (1999) · Science · doi:10.1126/science.286.5440.735 · Cited by 3,876 · see citing works

The carboxy terminus of the .beta. amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease

Jarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022 · see citing works

Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity

Wolfe, M. S., Xia, W., Ostaszewski, B. L., Diehl, T. S., Kimberly, W. T., & Selkoe, D. J. (1999) · Nature · doi:10.1038/19077 · Cited by 1,913 · see citing works

Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein

De Strooper, B., Saftig, P., Craessaerts, K., Vanderstichele, H., Guhde, G., Annaert, W., Von Figura, K., & Van Leuven, F. (1998) · Nature · doi:10.1038/34910 · Cited by 1,818 · see citing works

Visualization of Aβ42(43) and Aβ40 in senile plaques with end-specific Aβ monoclonals: Evidence that an initially deposited species is Aβ42(43)

Iwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · see citing works

Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production

Citron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757 · see citing works

A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid

Mullan, M., Crawford, F., Axelman, K., Houlden, H., Lilius, L., Winblad, B., & Lannfelt, L. (1992) · Nature Genetics · doi:10.1038/ng0892-345 · Cited by 1,513 · see citing works

An Increased Percentage of Long Amyloid β Protein Secreted by Familial Amyloid β Protein Precursor (βApp ₇₁₇ ) Mutants

Suzuki, N., Cheung, T. T., Cai, X.-D., Odaka, A., Otvos, L., Eckman, C., Golde, T. E., & Younkin, S. G. (1994) · Science · doi:10.1126/science.8191290 · Cited by 1,471 · see citing works

Beta-amyloid neurotoxicity requires fibril formation and is inhibited by congo red.

Lorenzo, A., & Yankner, B. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.25.12243 · Cited by 1,324 · see citing works

Amyloid β-Protein Fibrillogenesis

Walsh, D. M., Lomakin, A., Benedek, G. B., Condron, M. M., & Teplow, D. B. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.35.22364 · Cited by 1,139 · see citing works

Apolipoprotein E genotyping by one-stage PCR

Wenham, P. R., Price, W. H., & Blundell, G. (1991) · The Lancet · doi:10.1016/0140-6736(91)92823-k · Cited by 1,070 · see citing works

Amyloid β-Protein Fibrillogenesis

Walsh, D. M., Hartley, D. M., Kusumoto, Y., Fezoui, Y., Condron, M. M., Lomakin, A., Benedek, G. B., Selkoe, D. J., & Teplow, D. B. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.36.25945 · Cited by 1,046 · see citing works

Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives

Mattson, M. P. (1997) · Physiological Reviews · doi:10.1152/physrev.1997.77.4.1081 · Cited by 1,006 · see citing works

Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons

Hartley, D. M., Walsh, D. M., Ye, C., Diehl, T. S., Vasquez, S., Vassilev, P., Teplow, D. B., & Selkoe, D. J. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-20-08876.1999 · Cited by 965 · see citing works

Release of Excess Amyloid β Protein from a Mutant Amyloid β Protein Precursor

Cai, X.-D., Golde, T. E., & Younkin, S. G. (1993) · Science · doi:10.1126/science.8424174 · Cited by 913 · see citing works

Targeting of cell-surface β-amyloid precursor protein to lysosomes: alternative processing into amyloid-bearing fragments

Haass, C., Koo, E., Mellon, A., Hung, A. Y., & Selkoe, D. (1992) · Nature · doi:10.1038/357500a0 · Cited by 901 · see citing works

Evidence that β-Amyloid Protein in Alzheimer's Disease Is Not Derived by Normal Processing

Sisodia, S. S., Koo, E. H., Beyreuther, K. T., Unterbeck, A., & Price, D. L. (1990) · Science · doi:10.1126/science.1691865 · Cited by 894 · see citing works

The cell biology of β-amyloid precursor protein and presenilin in Alzheimer's disease

Selkoe, D. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01363-4 · Cited by 862 · see citing works

Normal and Abnormal Biology of the Beta-Amyloid Precursor Protein

Selkoe, D. J. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.002421 · Cited by 827 · see citing works

The Pathogenesis of Senile Plaques

DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753 · see citing works

Amyloid precursor protein processing and Aβ 42 deposition in a transgenic mouse model of Alzheimer disease

Johnson‐Wood, K., Lee, M., Motter, R. N., Hu, K., Gordon, G., Barbour, R., Khan, K., Gordon, M. N., Tan, H. T., Games, D., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.4.1550 · Cited by 634 · see citing works

Water-soluble Aβ(N-40, N-42) oligomers in normal and Alzheimer disease brains

Kuo, Y.-M., Emmerling, M. R., Vigo-Pelfrey, C., Kasunic, T. C., Kirkpatrick, J. B., Murdoch, G. H., Ball, M. J., & Roher, A. E. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.8.4077 · Cited by 618 · see citing works

Plasma and Cerebrospinal Fluid Levels of Amyloid β Proteins 1-40 and 1-42 in Alzheimer Disease

Mehta, P. D., Pirttilä, T., Mehta, S. P., Sersen, E. A., Aisen, P. S., & Wisniewski, H. M. (2000) · Archives of Neurology · doi:10.1001/archneur.57.1.100 · Cited by 582 · see citing works

Transition-state analogue inhibitors of γ-secretase bind directly to presenilin-1

Esler, W. P., Kimberly, W. T., Ostaszewski, B. L., Diehl, T. S., Moore, C. L., Tsai, J.-Y., Rahmati, T., Xia, W., Selkoe, D. J., & Wolfe, M. S. (2000) · Nature Cell Biology · doi:10.1038/35017062 · Cited by 514 · see citing works

Mass spectrometry of purified amyloid beta protein in Alzheimer's disease.

Mori, H., Takio, K., OGAWARA, M., & Selkoe, D. J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41896-0 · Cited by 481 · see citing works

Apolipoprotein E4 allele in a population–based study of early–onset Alzheimer's disease

van Duijn, C. M., de Knijff, P., Cruts, M., Wehnert, A., Havekes, L. M., Albert Hofman, D., & Broeckhoven, C. V. (1994) · Nature Genetics · doi:10.1038/ng0594-74 · Cited by 453 · see citing works

Estimation of the Genetic Contribution of Presenilin-1 and -2 Mutations in a Population-Based Study of Presenile Alzheimer Disease

Cruts, M., van Duijn, C. M., Backhovens, H., den Broeck, M. V., Wehnert, A., Serneels, S., Sherrington, R., Hutton, M., Hardy, J., George‐Hyslop, P. S., et al. (1998) · Human Molecular Genetics · doi:10.1093/hmg/7.1.43 · Cited by 429 · see citing works

A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1

Crook, R., Verkkoniemi, A., Pérez‐Tur, J., Mehta, N. D., Baker, M. C., Houlden, H., Farrer, M. J., Hutton, M., Lincoln, S., Hardy, J., et al. (1998) · Nature Medicine · doi:10.1038/nm0498-452 · Cited by 347 · see citing works

Human apolipoprotein E: the Alzheimer's disease connection

Weisgraber, K. H., & Mahley, R. W. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.13.8940294 · Cited by 327 · see citing works

Amino-terminal Deletions Enhance Aggregation of β-Amyloid Peptides in Vitro

Pike, C. J., Overman, M. J., & Cotman, C. W. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.41.23895 · Cited by 302 · see citing works

The Profile of Soluble Amyloid β Protein in Cultured Cell Media

Wang, R., Sweeney, D. A., Gandy, S., & Sisodia, S. S. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.50.31894 · Cited by 293 · see citing works

Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease

Gowing, E., Roher, A. E., Woods, A. S., Cotter, R. J., Chaney, M., Little, S. P., & Ball, M. J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)78080-6 · Cited by 223 · see citing works

Temporal Accrual of Complement Proteins in Amyloid Plaques in Down's Syndrome with Alzheimer's Disease

Stoltzner, S. E., Grenfell, T. J., Mori, C., Wisniewski, K. E., Wisniewski, T. M., Selkoe, D. J., & Lemere, C. A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64753-0 · Cited by 187 · see citing works

Predominant deposition of amyloid-beta 42(43) in plaques in cases of Alzheimer's disease and hereditary cerebral hemorrhage associated with mutations in the amyloid precursor protein gene.

Mann, D. M. A., Iwatsubo, T., Ihara, Y., Cairns, N. J., Lantos, P. L., Bogdanović, N., Lannfelt, L., Winblad, B. G., Maat–Schieman, M. L. C., & Rossor, M. N. (1996) · Europe PMC (PubMed Central) · Cited by 184 · see citing works

Amyloid Phenotype Characterization of Transgenic Mice Overexpressing both Mutant Amyloid Precursor Protein and Mutant Presenilin 1 Transgenes

McGowan, E. M., Sanders, S., Iwatsubo, T., Takeuchi, A., Saido, T. C., Zehr, C., Yu, X., Uljon, S., Wang, R., Mann, D. M. A., et al. (1999) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0243 · Cited by 180 · see citing works

Unusual phenotypic alteration of β amyloid precursor protein (βAPP) maturation by a new Val-715 → Met βAPP-770 mutation responsible for probable early-onset Alzheimer’s disease

Ancolio, K., Dumanchin‐Njock, C., Barelli, H., Warter, J., Brice, A., Campion, D., Frébourg, T., & Checler, F. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.4119 · Cited by 179 · see citing works

Aspartate residue 7 in amyloid β-protein is critical for classical complement pathway activation: Implications for Alzheimer's disease pathogenesis

Velázquez, P., Cribbs, D. H., Poulos, T. L., & Tenner, A. J. (1997) · Nature Medicine · doi:10.1038/nm0197-77 · Cited by 147 · see citing works

Characterization of New Polyclonal Antibodies Specific for 40 and 42 Amino Acid-Long Amyloid β Peptides: Their Use to Examine the Cell Biology of Presenilins and the Immunohistochemistry of Sporadic Alzheimer’s Disease and Cerebral Amyloid Angiopathy Cases

Barelli, H., Lebeau, A., Vizzavona, J., Delaère, P., Chevallier, N., Drouot, C., Marambaud, P., Ancolio, K., Buxbaum, J. D., Khorkova, O., et al. (1997) · Molecular Medicine · doi:10.1007/bf03401708 · Cited by 139 · see citing works

Behavioral Disturbances without Amyloid Deposits in Mice Overexpressing Human Amyloid Precursor Protein with Flemish (A692G) or Dutch (E693Q) Mutation

Kumar‐Singh, S., Dewachter, I., Moechars, D., Lübke, U., Jonghe, C. D., Ceuterick, C., Checler, F., Naidu, A., Cordell, B., Cras, P. P., et al. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.1999.0272 · Cited by 105 · see citing works

Amyloid β-Protein (Aβ) 1–40 But Not Aβ1–42 Contributes to the Experimental Formation of Alzheimer Disease Amyloid Fibrils in Rat Brain

Shin, R., Ogino, K., Kondo, A., Saido, T. C., Trojanowski, J. Q., Kitamoto, T., & Tateishi, J. (1997) · Journal of Neuroscience · doi:10.1523/jneurosci.17-21-08187.1997 · Cited by 96 · see citing works

Variant Alzheimer’s disease with spastic paraparesis

Verkkoniemi, A., Somer, M., Rinne, J. O., Myllykangas, L., Crook, R., Hardy, J., Viitanen, M. H., Kalimo, H., & Haltia, M. (2000) · Neurology · doi:10.1212/wnl.54.5.1103 · Cited by 96 · see citing works

Aberrant Splicing in the Presenilin-1 Intron 4 Mutation Causes Presenile Alzheimer's Disease by Increased A 42 Secretion

Jonghe, C. D., MarcCruts, Rogaeva, E. A., Tysoe, C. J., Singleton, A., Vanderstichele, H., Meschino, W. S., Dermaut, B., Vanderhoeven, I., Backhovens, H., et al. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.8.1529 · Cited by 93 · see citing works

Mutations in the Transmembrane Domain of APP Altering γ-Secretase Specificity

Lichtenthaler, S. F., Ida, N., Multhaup, G., Masters, C. L., & Beyreuther, K. T. (1997) · Biochemistry · doi:10.1021/bi971071m · Cited by 86 · see citing works

DNA diagnosis for hereditary cerebral hemorrhage with amyloidosis (Dutch type)

Bakker, E., Broeckhoven, C. V., Haan, J., Voorhoeve, E., Hul, W. V., Levy, E., Lieberburg, I. M., Carman, M. D., van Ommen, G. B., & Frangione, B. (1991) · Europe PMC (PubMed Central) · Cited by 78 · see citing works

Amyloid β protein 1–42/43 (Aβ 1–42/43) in cerebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study

Tamaoka, A., Sawamura, N., Odaka, A., Suzuki, N., Mizusawa, H., Shoji, S., & Mori, H. (1995) · Brain Research · doi:10.1016/0006-8993(95)00162-j · Cited by 72 · see citing works

Missense mutations in the chromosome 14 familial Alzheimer's disease presenilin 1 gene

Poorkaj, P., Sharma, V., Anderson, L., Nemens, E. J., Alonso, M. E., Orr, H. T., White, J. A., Heston, L. L., Bird, T. D., & Schellenberg, G. D. (1998) · Human Mutation · doi:10.1002/(sici)1098-1004(1998)11:3 · Cited by 60 · see citing works

MICROVESSEL DENSITY IN CORE BIOPSIES OF PROSTATIC ADENOCARCINOMA: A STAGE PREDICTOR?

Rogatsch, H., Hittmair, A., Reissigl, A. E., Mikuz, G., & Feichtinger, H. G. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199706)182:2 · Cited by 50 · see citing works

Alzheimer’s Disease: Lessons from Cell Biology

Kosik, K., Selkoe, D., & Christen, Y. (2011) · Research and Perspectives in Alzheimer’s Disease · doi:10.1007/978-3-642-79423-0 · Cited by 16 · see citing works

Specific ELISA systems for the detection of endogenous human and rodent ABETA40 and ABETA42

Mercken, M. H., Brepoels, E., Jongh, M. D., Laenen, W., Raeymaekers, P., & Geerts, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82862-6 · Cited by 6 · see citing works

Alzheimer disease models and human neuropathology: similarities and differences

Duyckaerts, C. J., Potier, M., & Delatour, B. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0312-8 · Cited by 441 · see citing works

Intraneuronal β-amyloid accumulation and synapse pathology in Alzheimer’s disease

Gouras, G. K., Tampellini, D., Takahashi, R. H., & Capetillo-Zarate, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0679-9 · Cited by 372 · see citing works

BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease

Ghosh, A. K., & Osswald, H. L. (2014) · Chemical Society Reviews · doi:10.1039/c3cs60460h · Cited by 361 · see citing works

Intraneuronal Aβ, non-amyloid aggregates and neurodegeneration in a Drosophila model of Alzheimer’s disease

Crowther, D. C., Kinghorn, K. J., Miranda, E., Page, R., Curry, J. A., Duthie, F., Gubb, D., & Lomas, D. A. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2004.12.025 · Cited by 351 · see citing works

Molecular Basis of Familial and Sporadic Alzheimer's Disease

Dorszewska, J., Prendecki, M., Oczkowska, A., Dezor, M., & Kozubski, W. P. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160314150501 · Cited by 329 · see citing works

Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Aβ42 and decreased Aβ40

Kumar‐Singh, S., Theuns, J., Broeck, B. V., Pirici, D. N., Vennekens, K., Corsmit, E., Cruts, M., Dermaut, B., Wang, R., & Broeckhoven, C. V. (2006) · Human Mutation · doi:10.1002/humu.20336 · Cited by 320 · see citing works

Intracellular accumulation of amyloid-beta – a predictor for synaptic dysfunction and neuron loss in Alzheimer’s disease

Bayer (2010) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2010.00008 · Cited by 252 · see citing works

A Cell Biological Perspective on Alzheimer's Disease

Annaert, W. G., & Strooper, B. D. (2002) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.18.020402.142302 · Cited by 218 · see citing works

Truncated beta‐amyloid peptide species in pre‐clinical Alzheimer's disease as new targets for the vaccination approach

Sergeant, N., Bombois, S., Ghestem, A., Drobecq, H., Kostanjevečki, V., Missiaen, C., Wattez, A., David, J. P., Vanmechelen, E., Sergheraert, C., et al. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01818.x · Cited by 213 · see citing works

Molecular consequences of amyloid precursor protein and presenilin mutations causing autosomal-dominant Alzheimer's disease

Weggen, S., & Beher, D. (2012) · Alzheimer's Research & Therapy · doi:10.1186/alzrt107 · Cited by 192 · see citing works

Dense-Core Plaques in Tg2576 and PSAPP Mouse Models of Alzheimer's Disease Are Centered on Vessel Walls

Kumar‐Singh, S., Pirici, D. N., McGowan, E. M., Serneels, S., Ceuterick, C., Hardy, J., Duff, K., Dickson, D. W., & Broeckhoven, C. V. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62995-1 · Cited by 179 · see citing works

Pathogenesis of cerebral amyloid angiopathy

Rensink, A. A. M., de Waal, R. M. W., Kremer, B. P. H., & Verbeek, M. M. (2003) · Brain Research Reviews · doi:10.1016/j.brainresrev.2003.08.001 · Cited by 159 · see citing works

Recent advances in the modeling of Alzheimer’s disease

Sasaguri, H., Hashimoto, S., Watamura, N., Sato, K., Takamura, R., Nagata, K., Tsubuki, S., Ohshima, T., Yoshiki, A., Sato, K., et al. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.807473 · Cited by 157 · see citing works

Genomics of Alzheimer Disease

Rosenberg, R. N., Lambracht‐Washington, D., Yu, G., & Xia, W. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0301 · Cited by 145 · see citing works

Novel amyloid precursor protein gene missense mutation (D678N) in probable familial Alzheimer's disease

Wakutani, Y. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.010611 · Cited by 144 · see citing works

Wnt signaling in Alzheimer's disease: Up or down, that is the question

Boonen, R. A. C. M., van Tijn, P., & Živković, D. (2008) · Ageing Research Reviews · doi:10.1016/j.arr.2008.11.003 · Cited by 143 · see citing works

Novel Presenilin 1 Mutation (S170F) Causing Alzheimer Disease With Lewy Bodies in the Third Decade of Life

Snider, B. J., Norton, J. B., Coats, M. A., Chakraverty, S., Hou, C. E., Jervis, R., Lendon, C. L., Goate, A., McKeel, D. W., & Morris, J. C. (2005) · Archives of Neurology · doi:10.1001/archneur.62.12.1821 · Cited by 129 · see citing works

Elevation of β-Amyloid Peptide 2–42 in Sporadic and Familial Alzheimer's Disease and Its Generation in PS1 Knockout Cells

Wiltfang, J., Esselmann, H., Cupers, P., Neumann, M., Kretzschmar, H. A., Beyermann, M., Schleuder, D., Jahn, H., Rüther, E., Kornhuber, J., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102790200 · Cited by 126 · see citing works

Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia

Xia, D., Lianoglou, S., Sandmann, T., Calvert, M., Suh, J. H., Thomsen, E., Dugas, J., Pizzo, M. E., DeVos, S. L., Earr, T. K., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00547-7 · Cited by 124 · see citing works

Amyloid β 38, 40, and 42 species in cerebrospinal fluid: More of the same?

Schoonenboom, N. S. M., Mulder, C., van Kamp, G. J., Mehta, S. P., Scheltens, P., Blankenstein, M. A., & Mehta, P. D. (2005) · Annals of Neurology · doi:10.1002/ana.20508 · Cited by 120 · see citing works

Microbial involvement in Alzheimer disease development and progression

Bulgart, H. R., Neczypor, E. W., Wold, L. E., & Mackos, A. R. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00378-4 · Cited by 116 · see citing works

Dense-Core Senile Plaques in the Flemish Variant of Alzheimer's Disease Are Vasocentric

Kumar-Singh, S., Cras, P., Wang, R., Kros, J. M., van Swieten, J., Lübke, U., Ceuterick, C., Serneels, S., Vennekens, K., Timmermans, J.-P., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64207-1 · Cited by 114 · see citing works

Aminopeptidase A contributes to the N‐terminal truncation of amyloid β‐peptide

Sévalle, J., Amoyel, A., Robert, P. H., Fournié‐Zaluski, M., Roques, B. P., & Checler, F. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05950.x · Cited by 108 · see citing works

Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention

Peng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110 · see citing works

Osthole decreases beta amyloid levels through up-regulation of miR-107 in Alzheimer’s disease

Jiao, Y., Kong, L., Yao, Y., Li, S., Tao, Z., Yan, Y., & Yang, J. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.046 · Cited by 104 · see citing works

Genetics, Transcriptomics, and Proteomics of Alzheimers Disease

Papassotiropoulos, A., Fountoulakis, M., Dunckley, T. L., Stephan, D. A., & Reiman, E. M. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0418 · Cited by 103 · see citing works

Cerebral amyloid angiopathy: pathogenetic mechanisms and link to dense amyloid plaques

Kumar‐Singh, S. (2008) · Genes Brain & Behavior · doi:10.1111/j.1601-183x.2007.00380.x · Cited by 94 · see citing works

The Ubiquitin-Proteasome System and Molecular Chaperone Deregulation in Alzheimer’s Disease

Sulistio, Y. A., & Heese, K. (2015) · Molecular Neurobiology · doi:10.1007/s12035-014-9063-4 · Cited by 93 · see citing works

Alzheimer’s disease mutations in APP but not γ-secretase modulators affect epsilon-cleavage-dependent AICD production

Dimitrov, M. I., Alattia, J., Lemmin, T., Lehal, R., Fligier, A., Houacine, J., Hussain, I., Radtke, F., Peraro, M. D., Beher, D., et al. (2013) · Nature Communications · doi:10.1038/ncomms3246 · Cited by 92 · see citing works

AAV-Tau Mediates Pyramidal Neurodegeneration by Cell-Cycle Re-Entry without Neurofibrillary Tangle Formation in Wild-Type Mice

Jaworski, T., Dewachter, I., Lechat, B., Croes, S., Termont, A., Demedts, D., Borghgraef, P., Devijver, H., Filipkowski, R. K., Kaczmarek, L., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007280 · Cited by 89 · see citing works

Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome

Zis, P., & Strydom, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.024 · Cited by 88 · see citing works

Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease

Hunter, S., & Brayne, C. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.218 · Cited by 94 · see citing works

Familial Alzheimer’s mutations within APPTM increase Aβ42 production by enhancing accessibility of ε-cleavage site

Chen, W., Gamache, E., Rosenman, D. J., Xie, J., López, M. M., Li, Y., & Wang, C. (2014) · Nature Communications · doi:10.1038/ncomms4037 · Cited by 84 · see citing works

Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment

Theuns, J., Marjaux, E., Vandenbulcke, M., Laere, K. V., Kumar‐Singh, S., Bormans, G. M., Brouwers, N., den Broeck, M. V., Vennekens, K. M., Corsmit, E., et al. (2006) · Human Mutation · doi:10.1002/humu.20402 · Cited by 78 · see citing works

Dimerization of the transmembrane domain of amyloid precursor proteins and familial Alzheimer's disease mutants

Gorman, P. M., Kim, S., Guo, M., Melnyk, R. A., McLaurin, J., Fraser, P. E., Bowie, J. U., & Chakrabartty, A. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-17 · Cited by 78 · see citing works

β-Amyloid Protein Structure Determines the Nature of Cytokine Release From Rat Microglia

Lindberg, C., Selenica, M. B., Westlind‐Danielsson, A., & Schultzberg, M. (2005) · Journal of Molecular Neuroscience · doi:10.1385/jmn:27:1:001 · Cited by 76 · see citing works

Genetic Markers of Alzheimer’s Disease

Perković, M. N., & Pivac, N. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9721-0_3 · Cited by 75 · see citing works

Cerebral amyloid angiopathy is a pathogenic lesion in Alzheimer's disease due to a novel presenilin 1 mutation

Dermaut, B. (2001) · Brain · doi:10.1093/brain/124.12.2383 · Cited by 74 · see citing works

Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features

Giaccone, G., Morbin, M., Moda, F., Botta, M., Mazzoleni, G., Uggetti, A., Catania, M., Moro, M. L., Redaelli, V., Spagnoli, A., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0747-1 · Cited by 73 · see citing works

Mutations in APP have independent effects on Aβ and CTFγ generation

Hecimovic, S., Wang, J., Dolios, G., Martinez, M., Wang, R., & Goate, A. M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.04.018 · Cited by 70 · see citing works

The Backbone Dynamics of the Amyloid Precursor Protein Transmembrane Helix Provides a Rationale for the Sequential Cleavage Mechanism of γ-Secretase

Pester, O., Barrett, P. J., Hornburg, D., Hornburg, P., Pröbstle, R., Widmaier, S., Kutzner, C., Dürrbaum, M., Kapurniotu, A., Sanders, C. R., et al. (2012) · Journal of the American Chemical Society · doi:10.1021/ja3112093 · Cited by 70 · see citing works

β-Amyloid Precursor Protein Mutants Respond to γ-Secretase Modulators

Page, R. M., Gutsmiedl, A., Fukumori, A., Winkler, E., Haass, C., & Steiner, H. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.103283 · Cited by 68 · see citing works

Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy

Pérez-Garmendia, R., & Gevorkian, G. (2013) · Current Neuropharmacology · doi:10.2174/1570159x11311050004 · Cited by 65 · see citing works

Current Insights into Molecular Mechanisms of Alzheimer Disease and Their Implications for Therapeutic Approaches

Broeck, B. V., Broeckhoven, C. V., & Kumar‐Singh, S. (2007) · Neurodegenerative Diseases · doi:10.1159/000105156 · Cited by 65 · see citing works

Early Onset Alzheimer’s Disease and Oxidative Stress

Meraz‐Ríos, M. A., Franco-Bocanegra, D., Toral-Ríos, D., & Campos‐Peña, V. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/375968 · Cited by 62 · see citing works

Aberrant Amyloid Precursor Protein (APP) Processing in Hereditary Forms of Alzheimer Disease Caused by APP Familial Alzheimer Disease Mutations Can Be Rescued by Mutations in the APP GxxxG Motif

Munter, L. M., Botev, A., Richter, L., Hildebrand, P. W., Althoff, V., Weise, C., Kaden, D., & Multhaup, G. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.088005 · Cited by 61 · see citing works

Intraneuronal amyloid β and reduced brain volume in a novel APP T714I mouse model for Alzheimer's disease

Van Broeck, B., Vanhoutte, G., Pirici, D., Van Dam, D., Wils, H., Cuijt, I., Vennekens, K., Zabielski, M., Michalik, A., Theuns, J., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.10.016 · Cited by 60 · see citing works

Clinical Genetics of Alzheimer’s Disease

Zou, Z., Liu, C., Che, C., & Huang, H. (2014) · BioMed Research International · doi:10.1155/2014/291862 · Cited by 58 · see citing works

Genetics of Early-Onset Alzheimer Dementia

Rademakers, R., Cruts, M., & Broeckhoven, C. V. (2003) · The Scientific World JOURNAL · doi:10.1100/tsw.2003.39 · Cited by 57 · see citing works

Tau is central in the genetic Alzheimer–frontotemporal dementia spectrum

Dermaut, B., Kumar‐Singh, S., Rademakers, R., Theuns, J., Cruts, M., & Broeckhoven, C. V. (2005) · Trends in Genetics · doi:10.1016/j.tig.2005.09.005 · Cited by 56 · see citing works

Presenilin-1 Mutation L271V Results in Altered Exon 8 Splicing and Alzheimer's Disease with Non-cored Plaques and No Neuritic Dystrophy

Kwok, J. B., Halliday, G. M., Brooks, W. S., Dolios, G., Laudon, H., Murayama, O., Hallupp, M., Badenhop, R. F., Vickers, J. C., Wang, R., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211827200 · Cited by 56 · see citing works

Cerebral Small Vessel Disease in Sporadic and Familial Alzheimer Disease

Kalaria, R. N., & Falla, D. S. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.07.004 · Cited by 55 · see citing works

Mechanisms of neurodegeneration — Insights from familial Alzheimer’s disease

Chávez‐Gutiérrez, L., & Szaruga, M. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.03.005 · Cited by 54 · see citing works

β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Increases Amyloid Deposition in Brain Parenchyma but Reduces Cerebrovascular Amyloid Angiopathy in Aging BACE × APP[V717I] Double-Transgenic Mice

Willem, M., Dewachter, I., Smyth, N. R., Dooren, T. V., Borghgraef, P., Haass, C., & LEUVEN, F. V. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63419-0 · Cited by 54 · see citing works

Alzheimer’s Disease: An Overview of Major Hypotheses and Therapeutic Options in Nanotechnology

Agarwal, M., Alam, R., Haider, M. K., Malik, M. Z., & Kim, D.-K. (2020) · Nanomaterials · doi:10.3390/nano11010059 · Cited by 53 · see citing works

C9ORF72 repeat expansions and other FTD gene mutations in a clinical AD patient series from Mayo Clinic.

Wojtas, A., Heggeli, K., Finch, N. A., Baker, M. C., DeJesus‐Hernandez, M., Younkin, S. G., Dickson, D. W., Graff‐Radford, N. R., & Rademakers, R. (2012) · Europe PMC (PubMed Central) · Cited by 53 · see citing works

Looking for the link between plaques and tangles

Duyckaerts, C. J. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.12.014 · Cited by 53 · see citing works

The Genetics of Very Early Onset Alzheimer Disease

Filley, C. M., Rollins, Y. D., Alan Anderson, C., Arciniegas, D. B., Howard, K. L., Murrell, J. R., Boyer, P. J., Kleinschmidt-DeMasters, B. K., & Ghetti, B. (2007) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0b013e318145a8c8 · Cited by 53 · see citing works

Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimer’s Agents Based on Rational Design

Hoang, V.-H., Tran, P., Cui, M., Ngo, V. T. H., Ann, J., Park, J., Lee, J., Choi, K., Cho, H., Kim, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00098 · Cited by 52 · see citing works

In Vitro Studies of Flemish, Dutch, and Wild-Type β-Amyloid Provide Evidence for Two-Staged Neurotoxicity

Kumar‐Singh, S., Julliams, A., Nuydens, R., Ceuterick, C., Labeur, C., Serneels, S., Vennekens, K., Osta, P. V., Geerts, H., Strooper, B. D., et al. (2002) · Neurobiology of Disease · doi:10.1006/nbdi.2002.0529 · Cited by 52 · see citing works

An Iranian family with Alzheimer’s disease caused by a novel APP mutation (Thr714Ala)

Pasalar, P., Najmabadi, H., Noorian, A. R., Moghimi, B., Jannati, A., Soltanzadeh, A., Krefft, T. A., Crook, R., & Hardy, J. (2002) · Neurology · doi:10.1212/wnl.58.10.1574 · Cited by 51 · see citing works

UniProt genomic mapping for deciphering functional effects of missense variants

McGarvey, P. B., Nightingale, A., Luo, J., Huang, H., Martin, M. J., & Wu, C. H. (2019) · Human Mutation · doi:10.1002/humu.23738 · Cited by 49 · see citing works

Hippocampal metabolomics using ultrahigh-resolution mass spectrometry reveals neuroinflammation from Alzheimer’s disease in CRND8 mice

Lin, S., Liu, H., Kanawati, B., Liu, L., Dong, J., Li, M., Huang, J., Schmitt‐Kopplin, P., & Cai, Z. (2013) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-013-6825-1 · Cited by 47 · see citing works

From beta amyloid to altered proteostasis in Alzheimer’s disease

Bruni, A. C., Bernardi, L., & Gabelli, C. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101126 · Cited by 47 · see citing works

Alzheimer’s Disease: From Genetic Variants to the Distinct Pathological Mechanisms

Sun, Q., Xie, N., Tang, B., Li, R., & Shen, Y. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00319 · Cited by 46 · see citing works

Aspects of Neurodegeneration in the Canine Brain

Dimakopoulos, A. C., & Mayer, R. J. (2002) · Journal of Nutrition · doi:10.1093/jn/132.6.1579s · Cited by 46 · see citing works

Processing of Mutant β-Amyloid Precursor Protein and the Clinicopathological Features of Familial Alzheimer’s Disease

Bi, C., Bi, S., & Li, B. (2018) · Aging and Disease · doi:10.14336/ad.2018.0425 · Cited by 45 · see citing works

A fibril-specific, conformation-dependent antibody recognizes a subset of Aβ plaques in Alzheimer disease, Down syndrome and Tg2576 transgenic mouse brain

Sarsoza, F. M., Saing, T., Kayed, R., Dahlin, R., Dick, M. B., Broadwater-Hollifield, C., Mobley, S., Lott, I. T., Doran, E. W., Gillen, D. L., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0530-3 · Cited by 44 · see citing works

An African American family with early-onset Alzheimer disease and an APP (T714I) mutation

Edwards-Lee, T. A., Ringman, J. M., Chung, J. A., Werner, J. S., Morgan, A. R., George‐Hyslop, P. S., Thompson, P. M., Dutton, R. A., Mlikotic, A., Rogaeva, E. A., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000149761.70566.3e · Cited by 43 · see citing works

Hereditary cerebral hemorrhage with amyloidosis dutch type (AβPP 693): decreased plasma amyloid-β 42 concentration

Bornebroek, M., Jonghe, C. D., Haan, J., Kumar‐Singh, S., Younkin, S., Roos, R. A. C., & Broeckhoven, C. V. (2003) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.08.019 · Cited by 43 · see citing works

Sorting Out the Role of the Sortilin-Related Receptor 1 in Alzheimer’s Disease

Barthelson, K., Newman, M., & Lardelli, M. T. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-200177 · Cited by 42 · see citing works

Modeling of Tau-Mediated Synaptic and Neuronal Degeneration in Alzheimer's Disease

Jaworski, T., Kügler, S., & LEUVEN, F. V. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/573138 · Cited by 42 · see citing works

Autosomal‐dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aβ production

Suárez-Calvet, M., Belbin, O., Pera, M., Badiola, N., Magrané, J., Guardia-Laguarta, C., Muñoz, L., Colom-Cadena, M., Clarimón, J., & Lleó, A. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12466 · Cited by 39 · see citing works

The Amyloid-Tau-Neuroinflammation Axis in the Context of Cerebral Amyloid Angiopathy

Cisternas, P., Taylor, X., & Lasagna‐Reeves, C. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246319 · Cited by 41 · see citing works

Dissecting Alzheimer disease in Down syndrome using mouse models

Choong, X. Y., Tosh, J., Pulford, L. J., & Fisher, E. (2015) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2015.00268 · Cited by 40 · see citing works

Untitled work

(2009) · PubMed · Cited by 40 · see citing works

Substrate processing in intramembrane proteolysis by γ-secretase – the role of protein dynamics

Langosch, D., & Steiner, H. (2016) · Biological Chemistry · doi:10.1515/hsz-2016-0269 · Cited by 39 · see citing works

The Uppsala APP deletion causes early onset autosomal dominant Alzheimer’s disease by altering APP processing and increasing amyloid β fibril formation

de la Vega, M. P., Giedraitis, V., Michno, W., Kilander, L., Güner, G., Zielinski, M., Löwenmark, M., Brundin, R., Danfors, T., Söderberg, L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc6184 · Cited by 39 · see citing works

Pharmacokinetic and Pharmacodynamic Effects of a γ‐Secretase Modulator, PF ‐06648671, on CSF Amyloid‐β Peptides in Randomized Phase I Studies

Ahn, J. E., Carrieri, C., Cruz, F. D., Fullerton, T., Hajós‐Korcsok, É., He, P., Kantaridis, C., Leurent, C., Liu, R., Mancuso, J. Y., et al. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1570 · Cited by 38 · see citing works

Hereditary and Sporadic Forms of Aβ-Cerebrovascular Amyloidosis and Relevant Transgenic Mouse Models

Kumar‐Singh, S. (2009) · International Journal of Molecular Sciences · doi:10.3390/ijms10041872 · Cited by 38 · see citing works

Evidence from Solid-State NMR for Nonhelical Conformations in the Transmembrane Domain of the Amyloid Precursor Protein

Lu, J., Yau, W., & Tycko, R. (2011) · Biophysical Journal · doi:10.1016/j.bpj.2010.12.3696 · Cited by 37 · see citing works

The Amyloid Cascade Hypothesis

Castellani, R. J., Jamshidi, P., Plascencia‐Villa, G., & Perry, G. L. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.10.014 · Cited by 36 · see citing works

Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimer’s Agents by Structure-Based Design

Hoang, V.-H., Ngo, V. T. H., Cui, M., Mạnh, N. V., Tran, P., Ann, J., Ha, H.-J., Kim, H., Choi, K., Kim, Y.-H., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00751 · Cited by 35 · see citing works

Molecular Determinants and Thermodynamics of the Amyloid Precursor Protein Transmembrane Domain Implicated in Alzheimer's Disease

Wang, H., Barreyro, L., Provasi, D., Djemil, I., Torres-Arancivia, C., Filizola, M., & Ubarretxena‐Belandia, I. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.03.028 · Cited by 35 · see citing works

Current biomarkers and treatment strategies in Alzheimer disease: An overview and future perspectives

Bhole, R. P., Chikhale, R. V., & Rathi, K. M. (2023) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2023.11.003 · Cited by 34 · see citing works

Homozygous carriers of APP A713T mutation in an autosomal dominant Alzheimer disease family

Conidi, M. E., Bernardi, L., Puccio, G., Smirne, N., Muraca, M. G., Curcio, S. A. M., Colao, R., Piscopo, P., Gallo, M., Anfossi, M., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001648 · Cited by 32 · see citing works

Effects of Intrinsic and Extrinsic Factors on Aggregation of Physiologically Important Intrinsically Disordered Proteins

Breydo, L., Redington, J., & Uversky, V. N. (2016) · International review of cytology · doi:10.1016/bs.ircmb.2016.08.011 · Cited by 29 · see citing works

APP intracellular domain formation and unaltered signaling in the presence of familial Alzheimer’s disease mutations

Bergman, A., Religa, D., Karlström, H., Laudon, H., Winblad, B. G., Lannfelt, L., Lundkvist, J., & Näslund, J. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(03)00117-4 · Cited by 27 · see citing works

Immunodominant epitope and properties of pyroglutamate-modified Aβ-specific antibodies produced in rabbits

Acero, G., Manoutcharian, K., Vasilevko, V., Munguía, M. E., Govezensky, T., Coronas, G., Luz-Madrigal, A., Cribbs, D. H., & Gevorkian, G. (2009) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.06.003 · Cited by 26 · see citing works

Advances in the cell biology of the trafficking and processing of amyloid precursor protein: impact of familial Alzheimer's disease mutations

Wang, J., Fourrière, L., & Gleeson, P. A. (2024) · Biochemical Journal · doi:10.1042/bcj20240056 · Cited by 25 · see citing works

γ-Secretase: Substrates and Inhibitors

Rochette, M. J., & Murphy, M. P. (2002) · Molecular Neurobiology · doi:10.1385/mn:26:1:081 · Cited by 24 · see citing works

An APP ectodomain mutation outside of the Aβ domain promotes Aβ production in vitro and deposition in vivo

Zhang, X., Zhang, C. M., Prokopenko, D., Liang, Y., Zhen, S. Y., Weigle, I. Q., Han, W., Aryal, M., Tanzi, R. E., & Sisodia, S. S. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20210313 · Cited by 23 · see citing works

Differential and substrate-specific inhibition of γ-secretase by the C-terminal region of ApoE2, ApoE3, and ApoE4

Hou, X., Zhang, X., Zou, H., Guan, M., Fu, C., Wang, W., Zhang, Z.-R., Geng, Y., & Chen, Y. (2023) · Neuron · doi:10.1016/j.neuron.2023.03.024 · Cited by 22 · see citing works

Molecular and clinical insights into protein misfolding and associated amyloidosis

Pande, M., & Srivastava, R. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111753 · Cited by 21 · see citing works

Lessons from genome‐wide association studies findings in Alzheimer's disease

Moraes, C. F., Lins, T. C. D. L., CARMARGOS, E. F., Naves, J. O. S., Pereira, R. W., & Nóbrega, O. D. T. (2011) · Psychogeriatrics · doi:10.1111/j.1479-8301.2011.00378.x · Cited by 19 · see citing works

Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer’s agents: Structure-activity relationship study of Arg-mimetic region

Ngo, V. T. H., Hoang, V.-H., Tran, P., Ann, J., Cui, M., Park, G., Choi, S., Lee, J., Kim, H. Y., Ha, H.-J., et al. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.01.015 · Cited by 19 · see citing works

Early and progressive deficit of neuronal activity patterns in a model of local amyloid pathology in mouse prefrontal cortex

Koukouli, F., Rooy, M., & Maskos, U. (2016) · Aging · doi:10.18632/aging.101136 · Cited by 19 · see citing works

Disordered proteins in dementia

Ingelsson, M., & Hyman, B. T. (2002) · Annals of Medicine · doi:10.1080/078538902320322529 · Cited by 19 · see citing works

Histological and immunohistochemical characteristics of cerebral amyloid angiopathy in elderly dogs

Nešić, S., Kukolj, V., Marinković, D., Vučićević, I., & Jovanović, M. (2016) · Veterinary Quarterly · doi:10.1080/01652176.2016.1235301 · Cited by 18 · see citing works

Fractal analysis of amyloid plaques in Alzheimer's disease patients and mouse models

Pirici, D. N., Cauwenberghe, C. V., Broeckhoven, C. V., & Kumar‐Singh, S. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.10.010 · Cited by 18 · see citing works

Using γ-Secretase Inhibitors to Distinguish the Generation of the Aβ Peptides Terminating at Val-40 and Ala-42

Paganetti, P., & Staufenbiel, M. (2003) · Humana Press eBooks · doi:10.1385/1-59259-195-7:239 · Cited by 3 · see citing works

Unusual Aß amyloid deposition in Alzheimer's disease due to an APP T7141 mutation at the γ42-secretase site

Jonghe, C. D., Kumar‐Singh, S., Cruts, M., Kleinert, R., Vanderstichele, H., Vanmechelen, E., Kroisel, P. M., & Broeckhoven, C. V. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)82241-1 · Cited by 2 · see citing works

Mutant presenilins specifically elevate the levels of the 42 residue β-amyloid peptide in vivo: evidence for augmentation of a 42-specific γ secretase

Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., Copeland, N. G., Lee, M. K., Younkin, L. H., Wagner, S. L., et al. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh019 · Cited by 1,575 · see citing works

Effects of γ‐secretase cleavage‐region mutations on APP processing and Aβ formation: interpretation with sequential cleavage and α‐helical model

Tan, J., Mao, G., Cui, M., Kang, S., Lamb, B. T., Wong, B., Sy, M., & Xu, X. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05643.x · Cited by 18 · see citing works

P‐012: Sequence around the ζ‐cleavage site plays a key role in γ‐secretase‐mediated app processing and aβ formation

Tan, J., Mao, G., Cui, M., & Xu, X. (2007) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2007.04.228